Ot­su­ka pays Ake­bia $55M to for­mal­ly end vadadu­s­tat part­ner­ship, wav­ing good­bye to the $1B deal

Last month, Ot­su­ka de­cid­ed to call off its vadadu­s­tat col­lab­o­ra­tion with Ake­bia Ther­a­peu­tics af­ter the drug was re­ject­ed at the FDA. Now, we know how much the com­pa­ny paid Ake­bia to wash its hands of the deal.

Ot­su­ka will send $55 mil­lion to Ake­bia to of­fi­cial­ly ter­mi­nate two part­ner­ships for both US and glob­al rights, the first of which was signed back in 2016 and promised about $1 bil­lion. As a re­sult, Ake­bia will re­gain all rights to the drug in the US, Eu­rope, Chi­na, Rus­sia, Cana­da, Aus­tralia, the Mid­dle East and oth­er cer­tain ter­ri­to­ries, the biotech said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER